← All work
06i-calQ / ELADO / Activgard2013–2014

Point-of-care diagnostics · Product localisation · Android

ThyroSpot India Localisation

The localisation problem was not translating a screen. It was controlling every condition between a biological sample and a repeatable reading.

MedtechLocalisationAndroidMarket entry
RoleProduct Manager
Period2013–2014
StageIndia-market adaptation · small-scale field testing · market-entry preparation
SystemDisposable TSH cassette · reader · controlled illumination · Android app
System Explainer Portfolio-created model of the diagnostic product chain · not clinical UI
Evidence key

Every product visual is labelled by provenance, so original work is never confused with a portfolio-created explanation.

Original Product Artifact Surviving source material from the product work.

A genuine working document, wireframe, screenshot or output that can be shown publicly.

Portfolio Reconstruction Recreated from documented product logic using synthetic or anonymised content.

A recreated product view grounded in the original work, using synthetic or anonymised information.

System Explainer Created for this portfolio to explain product logic; not product UI.

A simplified model created for this portfolio to explain system behaviour, workflow or product logic.

01

The product problem beneath localisation

A diagnostic platform could not be moved into a new market as though it were only an app.

Medtech · Point-of-care diagnostics · Android · Product localisation · Market entry

Clinical workflow, sample handling, operator training, environmental conditions, phone behaviour, storage, offline use, regulation, service, pricing and distribution all influenced whether the system could operate consistently. The product task was to preserve the diagnostic workflow while redesigning the surrounding operating environment for India.

01 Biological input

The sample and cassette create their own operating constraints.

Handling sequence, timing, storage and operator technique all affect what reaches the imaging stage. The interface could not compensate for an uncontrolled pre-analytic workflow.

02 Optical capture

A camera reading is only meaningful when alignment and illumination are controlled.

The reader had to position the cassette at the correct focal relationship while the light enclosure reduced variation in image acquisition.

03 Device environment

A general-purpose phone introduces uncontrolled behaviour.

Notifications, settings, unrelated apps, operating-system differences and connectivity assumptions could all interrupt or alter a high-stakes workflow.

04 Market operation

Regulation, distribution, service and training shape the product itself.

India entry required the physical system, software workflow and operating model to be considered together rather than as separate launch workstreams.

02

The end-to-end diagnostic product

The result was produced by a chain of chemistry, hardware, optics, software and operator actions.

The smartphone app sat near the end of the workflow. Before software could analyse anything, the sample had to move through a disposable assay, the cassette had to be aligned with the camera and image acquisition had to happen under defined illumination.

System Explainer Reconstructed from documented system behaviour
Biological inputSample
Image analysisSignal → resultControl · test · calibration
01Sample

Serum / plasma enters a controlled assay workflow

02Disposable cassette

Test, control and calibration signals become visible

03Reader alignment

Cassette and camera are held in a defined relationship

04Controlled illumination

The light-box stabilises image acquisition conditions

05Image analysis

Android software identifies and quantifies the optical signal

06Quantitative result

The result is stored and interpreted within the clinical workflow

Product principleThe quality of the result depends on the weakest uncontrolled step in the chain.
03

Turn measurement variability into explicit product controls

The localisation work started by asking what could vary—and what the product had to control.

Each source of variation created a corresponding product responsibility. Some controls lived in hardware, some in Android, some in instructions and some in the operating model around storage, training and service.

System Explainer Portfolio-created control model · not a clinical risk file
Measurement axisWhat can varyProduct control
01 Sample

Preparation · timing · condition

Guided handling sequence
02 Cassette

Position · test/control visibility

Indexed physical fit
03 Optics

Focus · angle · camera alignment

Reader attachment
04 Light

Ambient illumination

Defined light enclosure
05 Device

Apps · settings · OS behaviour

Standardised Android environment
06 Operator

Sequence · interpretation · training

Constrained workflow and instructions
04

Three decisions that made localisation operable

The highest-leverage choices were about control, not cosmetic adaptation.

The product decisions connected consumer hardware, a biological assay and field operations into one repeatable workflow. Each decision reduced a different form of uncertainty before the result reached the user.

01Instrument decision

Treat the smartphone as part of the medical instrument.

The phone was not merely a display. Its camera, operating system, installed software and settings directly participated in image acquisition and result generation. The India configuration therefore treated the handset, reader and app as one controlled product system.

System Explainer Portfolio-created model of the decision logic
02Measurement decision

Control the conditions around image capture.

Image analysis depended on a repeatable view of the cassette. The reader attachment aligned the cassette with the smartphone camera, while the light enclosure reduced illumination variability. Calibration and control signals remained part of the workflow rather than hidden technical details.

System Explainer Portfolio-created model of the decision logic
03Localisation decision

Localise the entire operating workflow, not only the interface.

The India work covered cassette handling, software sequence, operator instructions, device interaction, offline use, training, storage, service and market-entry dependencies. A translated interface would have left the most consequential workflow risks untouched.

System Explainer Portfolio-created model of the decision logic
05

Make a general-purpose device behave like a dedicated instrument

The Android environment was intentionally reduced around the diagnostic workflow.

The India-specific configuration removed unnecessary device behaviour and prioritised a kiosk/POS-style operating mode. The core workflow did not depend on continuous connectivity, and test images and analysis results could remain stored on the handset.

Portfolio Reconstruction Controlled Android operating environment
01Locked environmentKiosk / POS-style operation
02Primary workflowDiagnostic application only
03ConnectivityCore test usable offline
04ResultsStored locally on the handset
05Device behaviourStandardised configuration
System Explainer Constrained workflow from device start to stored result
01Power on
02Diagnostic app launches
03Select test
04Capture cassette
05Analyse image
06Review and store result
06

From clinical discovery to India-readiness work

I connected clinical discovery, product localisation and Android-side delivery into one India-readiness programme.

My scope covered market and user research, hospital and laboratory workflow discovery, beta-test planning, Android customisation, kiosk-mode operation, diagnostic application work, workflow localisation, clinical stakeholder coordination, distributor and regulatory workstreams, and go-to-market planning. The work required translating field constraints into product and engineering decisions across software, hardware and operations.

01

India market, user and clinical-workflow research

02

Beta-test planning and small-scale field testing

03

Android customisation and kiosk-mode operating model

04

Diagnostic application and workflow localisation

05

Cross-functional coordination across clinical, hardware and software work

06

Regulatory, import, validation, service and distribution preparation

System Explainer Discovery → configuration → small-scale field testing → market-entry preparation
01Assess India context
02Map clinical workflow
03Identify variability and dependency risks
04Define India configuration
05Customise Android and app workflow
06Plan and run beta testing
07Refine operating model
08Prepare market-entry workstreams
Localisation principle

Preserve the diagnostic logic while adapting the device, workflow and operating environment around it.

07

Evidence-bounded outcomes

Delivered work

What changed as the platform was adapted for the Indian operating context.

01

Completed India-market product assessment and clinical-workflow discovery.

02

Led Android customisation, kiosk-mode operation and diagnostic-application work.

03

Localised the end-to-end operating workflow rather than only the user interface.

04

Conducted small-scale field testing of the India-specific configuration.

05

Supported regulatory, import, validation, local-manufacturing, laboratory and distributor workstreams.

Evidence boundary

The work reached India-market adaptation, product localisation and small-scale field testing. This case does not claim Indian regulatory approval, commercial launch, large-scale clinical validation or clinical impact.

Public evidence note

The public product views are portfolio reconstructions based on documented system behaviour. Private partner, regulatory, clinical and field-testing materials are not published.

08

What the work changed in how I think

A high-stakes product is the complete chain that produces the result.

01

The app was only one component of the product.

Chemistry, physical alignment, illumination, software and operator behaviour formed one measurement chain.

02

Workflow variability can become product risk.

In high-stakes environments, uncontrolled steps before and after the interface can matter more than the interface itself.

03

Controlled simplicity can be safer than flexibility.

Restricting device behaviour reduced operational uncertainty and kept the diagnostic workflow primary.

04

Market entry belongs inside product strategy.

Regulation, service, distribution and device standardisation materially influenced the India product configuration.